drugset / Trial / NCT03333265

Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride

NCT03333265

Phase 2/3 Completed 100 enrolled Xijing Hospital of Digestive Diseases
RandomizedParallel-groupTriple-blindPrevention

Summary

In recent years, Berberine hydrochloride has been reported to inhibit cancer cell proliferation and to be cytotoxic towards cancer cells. Patients with familial adenomatous polyposis have a nearly 100 percent risk of colorectal cancer. The aim of this study is to investigate the chemopreventive effects Berberine hydrochlorid on the regression of colorectal adenomas.

Timeline

Start
2017-09-01
Primary completion
2020-08-31
Completion
2021-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Berberine Traditional medicine (herbal / TCM) 100 mg Oral
Subject Berberine Traditional medicine (herbal / TCM) 300 mg Oral

Indications